

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>HCC-G (1 of 2) External Request Submission received from Bristol Myers Squibb (07/26/21) notifying the Hepatobiliary Cancers Panel of the U.S. withdrawal of the indication for nivolumab as a single agent for the treatment of patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib.</p>	<p>Based on a review of the data, the panel consensus supported updating the recommendation for nivolumab as a Subsequent-Line Therapy for Hepatocellular Carcinoma if Disease Progression. Nivolumab was kept as a subsequent-line treatment option for patients with HCC (Child-Pugh Class B only)</p>				
	<p>Nivolumab (Child-Pugh Class B only) changed from category 2A to category 2B</p>	11	6	3	11
	<p>Other Recommended Regimens: Nivolumab was removed as a treatment option for patients with Child-Pugh Class A.</p>	10	6	4	11
	<p>Nivolumab (Child-Pugh Class B only) was moved from Other Recommended Regimens to Useful in Certain Circumstances.</p> <p>See Submission</p>	13	1	6	11